Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22996648 | 0.90 | CYP2C9 (0.39) | AAK1USP30NOTUMCYP2C9CYP2C19 | |
| SCHEMBL30171939 | 0.90 | CYP2C9 (0.39) | AAK1USP30NOTUMCYP2C9CYP2C19 | |
| SCHEMBL21956947 | 0.89 | AAK1 (0.35) | AAK1USP30NOTUMCYP2C9CYP2C19 | |
| SCHEMBL21591073 | 0.87 | MTNR1A (0.41) | AAK1USP30NOTUMMAPTMTNR1A | |
| SCHEMBL679324 | 0.85 | GAA (0.45) | CYP2C9CYP2C19NPSR1GRM6MTNR1A | |
| SCHEMBL14289250 | 0.83 | CYP2C9 (0.47) | CYP2C9CYP2C19NPSR1GRM6MTNR1A | |
| SCHEMBL25304437 | 0.83 | CYP2C9 (0.37) | CYP2C9CYP2C19NPSR1GRM6MTNR1A | |
| SCHEMBL15359768 | 0.81 | GRM6 (0.40) | CYP2C9CYP2C19NPSR1MAPTGRM6 | |
| SCHEMBL16546183 | 0.81 | AAK1 (0.38) | AAK1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22982859 | 0.81 | AAK1 (0.37) | AAK1USP30NOTUMCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-4724431-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF | Beone Medicines I GmbH (CH) | 2026-04-15 | — | — | EP | disclosed |
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-03-26 | — | — | US | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| EP-4541422-A2 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | Gilead Sciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| CN-119462635-A | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., LTD. (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | AAK1 181/4885USP30 3439/4885NOTUM 4142/4885 |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | AAK1 263/4885USP30 4688/4885NOTUM 3696/4885 |
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | SIK1, CHUK, SIK2 | AAK1 300/4885USP30 4736/4885NOTUM 3338/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | AAK1 3259/4885USP30 2839/4885NOTUM 4256/4885 |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | ITGB4, ITGA4, ITGA2 | AAK1 4515/4885USP30 4535/4885NOTUM 3615/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | AAK1 263/4885USP30 4688/4885NOTUM 3696/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | AAK1 3307/4885USP30 2957/4885NOTUM 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.